Intensity Therapeutics Files 8-K

TL;DR

INTENSITY THERAPEUTICS (INTT) FILED AN 8-K ON 7/3/24 - MATERIAL AGREEMENT & FINANCIALS.

AI Summary

On July 3, 2024, Intensity Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, incorporated in Delaware, is involved in biological products and is headquartered in Westport, CT.

Why It Matters

This filing indicates significant corporate actions or financial updates for Intensity Therapeutics, Inc., which could impact investors and stakeholders.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K report, which typically discloses material events or financial updates without immediate, significant risk implications.

Key Players & Entities

• INTENSITY THERAPEUTICS, INC. (company) — Registrant
• July 3, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 001-41109 (company_id) — SEC File Number
• 46-1488089 (tax_id) — IRS Employer Identification No.
• 1 Enterprise Drive, Suite 430 Shelton, CT 06484-4779 (address) — Principal Executive Offices
• 203-221-7381 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — nge on Which Registered: Common Stock, $0.0001 par value per share INTS The Nasdaq Sto
• $15,000,000 — ell and issue, from time to time, up to $15,000,000 of shares of its common stock (the "Sha

Filing Documents

• intensity-20240703.htm (8-K) — 30KB
• 0001628280-24-031098.txt ( ) — 159KB
• intensity-20240703.xsd (EX-101.SCH) — 2KB
• intensity-20240703_lab.xml (EX-101.LAB) — 23KB
• intensity-20240703_pre.xml (EX-101.PRE) — 13KB
• intensity-20240703_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On July 3, 2024, Intensity Therapeutics, Inc. (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), pursuant to which the Company may sell and issue, from time to time, up to $15,000,000 of shares of its common stock (the "Shares") through Wainwright as the Company's sales agent (the "ATM Offering"). The Company has no obligation to sell any of the Shares and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement pursuant to its terms. Sales of the Shares, if any, under the Sales Agreement may be made in transactions that are deemed to be "at-the-market" equity offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including, without limitation, sales made directly on or through The Nasdaq Capital Market, the trading market for the Company's common stock, or any other existing trading market in the United States for the Company's common stock, sales made to or through a market maker other than on an exchange or otherwise, directly to Wainwright as principal in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or in any other method permitted by law. Subject to the terms and conditions of the Sales Agreement, Wainwright will use its commercially reasonable efforts to sell the Shares from time to time based upon the Company's instructions (including any price, time or size limits or other parameters or conditions the Company may impose). The Company will pay Wainwright a commission of 3.0% of the gross sales price of the Shares sold under the Sales Agreement. The Company has also provided Wainwright with customary indemnification rights and has agreed to reimburse Wainwright for certain expenses. The offer and sale of the Shares pursuant to the ATM Offering will terminate upon the earlier of

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 At The Market Offering Agreement, dated July 3, 2024, by and between Intensity Therapeutics, Inc. and H.C. Wainwright & Co., LLC. (incorporated by reference to Exhibit 1.3 of the Company's Registration Statement on Form S-3 filed on July 3, 2024). 104 Cover Page Interactive Data File (formatted in Inline XBRL). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 3, 2024 Intensity Therapeutics, Inc. By: /s/ Lewis H. Bender Name: Lewis H. Bender Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR